The biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing mutant blood stem cells to become shorter-lived white blood cells, according to a study by Weill Cornell Medicine investigators. Because the broad activity of interferon-alpha can induce significant side effects, developing more focused strategies based on these mechanistic findings could meet an important need in cancer therapy.

Cytological tests are a common method of screening for cancer cells in stained cell samples. Using a microscope, pathologists examine cells collected from bodily fluids, looking for telltale signs of malignancy, like enlarged nuclei or abnormal cell shapes. Owing to their minimally invasive nature, these tests are widely used for early cancer screening and diagnosis.

Type 2 diabetes increases the risk of chronic kidney disease, making prevention of kidney failure a key part of treatment. Newer diabetes medications, including GLP-1s and SGLT2 inhibitors, can reduce the risk of kidney disease, but previous studies have included large proportions of patients who already had signs of kidney damage, making it unclear whether the findings applied to patients without kidney damage.